Cell Therapeutics (CTIC) ADC Cell Therapeutics (9 lettori)
- Creatore Discussione tucciotrader
- Data di Inizio
s66
Forumer attivo
scrivere in inglese dopo un saluto in italiano
già questo fà capire di che monnezza sei composto ! TOGLIETEVI DAI KOGLION X CORTESIA ! PENSATE AL PAESE AMERICA FALLITO E GESTITO DA 4 VENDUTI ! 
rodeotto
Nuovo forumer
Ieri ho trovato l'articolo.............e l'ho postato............
strano che sia riportato solo su ........TRADINGVIEW..........nessun altro accumulatore di notizie su CTIC neanche twitter lo riporta
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments - Seeking Alpha
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments
December 18, 2012 | includes: CTIC, GNVC
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
When it comes to the biotech sector, many stocks that trade under $5/share are considered to be very speculative. As a result, I wanted to focus on companies that could benefit from developments within their specific markets. In this article I've chosen two companies that have met the follow criteria:
Each company must trade below $2/share
Each company must have a Market Cap under $100 million
Each company must have announced significant developments in the last 24 hours
Cell Therapeutics (CTIC) which is based in Seattle, Washington engages "in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is also in the process of developing Pixuvri, a novel anthracycline derivative intended for the treatment of hematologic malignancies and solid tumors". (Yahoo! Finance)
From a fundamental perspective, shares of CTIC currently carry a market cap of $70 million, have traded down 50.13% since July 1st and are currently trading in-line with their 50 DMA and at a 43.83% discount to their 200 DMA.
CTIC data by YCharts
On December 17th it was announced that Cell Therapeutics published positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. If CTIC can continue to establish models that refrain from forming such oxygen-based species, these trials may be a step in the right direction.
strano che sia riportato solo su ........TRADINGVIEW..........nessun altro accumulatore di notizie su CTIC neanche twitter lo riporta
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments - Seeking Alpha
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments
December 18, 2012 | includes: CTIC, GNVC
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
When it comes to the biotech sector, many stocks that trade under $5/share are considered to be very speculative. As a result, I wanted to focus on companies that could benefit from developments within their specific markets. In this article I've chosen two companies that have met the follow criteria:
Each company must trade below $2/share
Each company must have a Market Cap under $100 million
Each company must have announced significant developments in the last 24 hours
Cell Therapeutics (CTIC) which is based in Seattle, Washington engages "in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is also in the process of developing Pixuvri, a novel anthracycline derivative intended for the treatment of hematologic malignancies and solid tumors". (Yahoo! Finance)
From a fundamental perspective, shares of CTIC currently carry a market cap of $70 million, have traded down 50.13% since July 1st and are currently trading in-line with their 50 DMA and at a 43.83% discount to their 200 DMA.
CTIC data by YCharts
On December 17th it was announced that Cell Therapeutics published positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. If CTIC can continue to establish models that refrain from forming such oxygen-based species, these trials may be a step in the right direction.
Ultima modifica:
ghiottolux
Forumer attivo
Chi e' professor giorgio minotti:
ecco:
RIVISTE SCIENTIFICHE, NOMINE PER MINOTTI | News
se non ce lo dice lui che il pixantrone non è cardiotossico, chi altri potrebbe dirlo?
ecco:
RIVISTE SCIENTIFICHE, NOMINE PER MINOTTI | News
se non ce lo dice lui che il pixantrone non è cardiotossico, chi altri potrebbe dirlo?
CELLISTA DOC
Nuovo forumer
Ricordo male, oppure sull'invocata "The Lancet", poco tempo fa, è stato pubblicato qualcosa sul PIX ???
Ghiottolux, tu che sei un eccellente segugio, troveresti il link ???
Grazie, e buona sera al Forum
Ghiottolux, tu che sei un eccellente segugio, troveresti il link ???
Grazie, e buona sera al Forum
ghiottolux
Forumer attivo
Ciao Leonida, spero che tu abbia ragione.....ed io pure che ho puntato su questo titolo!!!